Advanced therapies for pediatric solid tumors
Figure: Mechanism of action of Oncolytic Viruses (OV); Varela-Guruceaga et al; Cancers 2018.
High-grade tumors of the central nervous system are the most common malignant solid tumors in childhood. Of these tumors, primitive neuroectodermal tumors (PNETs), atypical teratoid rhabdoid tumors (ATRTs), diffuse intrinsic pontine glioma (DIPG), high-grade glioma (pHGG) and gliomatosis cerebri are a priority for our group. In addition, pediatric bone sarcomas are a genetically heterogeneous group of high-grade tumors with a high propensity to metastasize. Together with central nervous system tumors are the leading cause of death due to cancer in children and adolescents.
These entities are a major cause of disease and death in children and overall survival has not substantially improved in recent years, despite surgical treatment, radiation therapy, and multimodal chemotherapy. It is clear, therefore, that management of these diseases is suboptimal and that new targeted therapies are needed. The main objective of our laboratory is to develop new therapeutic strategies for pediatric solid tumors, brain tumors and sarcomas, by exploiting the immune system through the use of tumor-specific oncolytic viruses combined with other strategies that may potentiate this effect.
We use adenovirus Delta-24-RGD, designed to replicate specifically in cells with alterations of the RB1 cell-cycle regulation pathway, thus making it of particular interest for use in childhood tumors. We use this virus as a platform for developing other viruses that seek to exploit the immune system in order to obtain greater control over the disease.
Our project uses novel and relevant in vitro and in vivo models of pediatric brain tumors and sarcomas, with the intention of implementing these strategies in children with brain tumors.
Secondary goals of our laboratory are the search for new markers and understanding the underlying biology of these tumors.
Fecha de actualización: Noviembre 2018
"Our laboratory is interested in developing new therapeutic strategies for pediatric and adult brain tumors by modulating the immune system", Drs. Marta Alonso y Ana Patiño.